Search Result

Results for "

CDK1-IN-2

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (12) Aurora Kinase (1) Autophagy (2) Bcl-2 Family (1) Caspase (1) CDK (27) COX (1) GSK-3 (2) HDAC (1) HIV (2) mTOR (2) PI3K (2)
By Research Areas:	Cancer (27) Metabolic Disease (1)

Inhibitors & Agonists

Isotope-Labeled Compounds

Targets Recommended: AIM2 NEKs

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-112463

*CDK1-IN-2*	CDK	Cancer
CDK1-IN-2 is a *CDK1* inhibitor (IC₅₀: 5.8 μM) .

HY-10005

Flavopiridol Maximum Cited Publications 39 Publications Verification HMR-1275; Alvocidib; L86-8275	CDK Autophagy HIV Apoptosis	Cancer
Flavopiridol (Alvocidib) is a broad spectrum and competitive inhibitor of CDKs, inhibiting CDK1, CDK2, CDK4 with IC₅₀s of 30, 170, 100 nM, respectively.

HY-124760

hSMG-1 inhibitor 11e	mTOR PI3K CDK	Cancer
hSMG-1 inhibitor 11e is a potent and selective hSMG-1 kinase inhibitor with an IC₅₀ of <0.05 nM. hSMG-1 inhibitor 11e shows >900-fold selectivity over mTOR (IC₅₀ of 45 nM), PI3Kα/γ (IC₅₀s of 61 nM and 92 nM) and CDK1/CDK2 (IC₅₀s of 32 μM and 7.1 μM) .

HY-10006

Flavopiridol Hydrochloride Maximum Cited Publications 39 Publications Verification Alvocidib Hydrochloride; L86-8275 Hydrochloride; HMR-1275 Hydrochloride	CDK Autophagy HIV	Cancer
Flavopiridol Hydrochloride (Alvocidib Hydrochloride) is a broad inhibitor of CDK, competing with ATP to inhibit CDKs including CDK1, CDK2, CDK4 with IC₅₀s of 30, 170, 100 nM, respectively.

HY-15241

NVP-LCQ195 LCQ-195; AT9311	CDK	Cancer
NVP-LCQ195 (AT9311; LCQ195) is a small molecule heterocyclic inhibitor of CDK1, CDK2, CDK3 and CDK5 with IC50 of 1-42 nM.

HY-50943

AT7519 Hydrochloride 10+ Cited Publications	CDK Apoptosis	Cancer
AT7519 Hydrochloride is a potent inhibitor of CDKs, with IC₅₀s of 210, 47, 100, 13, 170, and <10 nM for CDK1, CDK2, CDK4 to CDK6, and CDK9, respectively.

HY-15569

NU6102	CDK	Cancer
NU6102 is a potent *CDK1* and CDK2 inhibitor with IC₅₀s of 9.5 nM and 5.4 nM for *CDK1/cyclinB* and CDK2/cyclinA3, respectively. NU6102 shows selectivity for *CDK1/CDK2* over CDK4 (IC₅₀ of 1.6 μM), DYRK1A (IC₅₀ of 0.9 μM), PDK1 (IC₅₀ of 0.8 μM) and ROCKII (IC₅₀ of 0.6 μM) .

HY-13914

Roniciclib BAY 1000394	CDK	Cancer
Roniciclib is an orally bioavailable pan-cyclin dependent kinase (CDK) inhibitor, with IC₅₀s of 5-25 nM for CDK1, CDK2, CDK3, CDK4, CDK7 and CDK9.

HY-50940

AT7519 10+ Cited Publications AT7519M	CDK Apoptosis	Cancer
AT7519 (AT7519M) as a potent inhibitor of CDKs, with IC₅₀s of 210, 47, 100, 13, 170, and <10 nM for CDK1, CDK2, CDK4 to CDK6, and CDK9, respectively.

HY-50940A

AT7519 TFA 10+ Cited Publications AT7519M TFA	CDK	Cancer
AT7519 (AT7519M) TFA as a potent inhibitor of CDKs, with IC₅₀s of 210, 47, 100, 13, 170, and <10 nM for CDK1, CDK2, CDK4 to CDK6, and CDK9, respectively.

HY-153221

QR-6401	CDK	Cancer
QR-6401 is an orally active and selective macrocyclic CDK2 inhibitor with IC₅₀ values of 0.37, 10, 22, 34 and 45 nM for CDK2/E1, CDK9/T1, *CDK1/A2, CDK6/D3* and CDK4/D1, respectively. QR-6401 has potent antitumor activity in an OVCAR3 ovarian cancer xenograft model. QR-6401 has the potential to be used in the study of cancer .

HY-124719

hSMG-1 inhibitor 11j 2 Publications Verification	PI3K mTOR GSK-3 CDK	Cancer
hSMG-1 inhibitor 11j, a pyrimidine derivative, is a potent and selective inhibitor of hSMG-1, with an IC₅₀ of 0.11 nM. hSMG-1 inhibitor 11j exhibits >455-fold selectivity for hSMG-1 over mTOR (IC₅₀=50 nM), PI3Kα/γ (IC₅₀=92/60 nM) and *CDK1/CDK2* (IC₅₀=32/7.1 μM). hSMG-1 inhibitor 11j can be used for the research of cancer .

HY-10329

JNJ-7706621 2 Publications Verification	Aurora Kinase CDK Apoptosis	Cancer
JNJ-7706621 is a potent aurora kinase inhibitor, and also inhibits *CDK1* and CDK2, with IC₅₀s of 9 nM, 3 nM, 11 nM, and 15 nM for *CDK1, CDK2*, aurora-A and aurora-B, respectively .

HY-10012

AZD-5438 10+ Cited Publications	CDK	Cancer
AZD-5438 is a potent *CDK1, CDK2*, and CDK9 inhibitor, with IC₅₀s of 16 nM, 6 nM, and 20 nM in cell-free assays, respectively. AZD-5438 shows less inhibition activity against GSK3β, CDK5 and CDK6 .

HY-15777S1

Ribociclib-d8 LEE011-d₈	CDK	Cancer
Ribociclib-d₈ is the deuterium labeled Ribociclib[1]. Ribociclib (LEE01) is a highly specific CDK4/6 inhibitor with IC50 values of 10 nM and 39 nM, respectively, and is over 1,000-fold less potent against the cyclin B/CDK1 complex[2].

HY-15491

AG-024322	COX Apoptosis	Cancer
AG-024322 is a potent ATP-competitive pan-CDK inhibitor against cell cycle kinases *CDK1, CDK2*, and CDK4 with K_i values in the 1-3 nM range . AG-024322 displays broad-spectrum anti-tumor activity and clear target modulation in vivo. AG-024322 induces cell apoptosis .

HY-157647

1-Stearoyl-2-Adrenoyl-sn-glycero-3-PC PC(18:0/22:4)	CDK Apoptosis	Cancer
1-Stearoyl-2-Adrenoyl-sn-glycero-3-PC (PC(18:0/22:4)) is an inhibitor of cyclin-dependent kinases (CDKs).? 1-Stearoyl-2-Adrenoyl-sn-glycero-3-PC induces apoptosis and inhibits the growth of various cancer cell lines .

HY-151409

CDK1-IN-5	CDK	Cancer
CDK1-IN-5 (10h) is a selective *CDK1* inhibitor with IC₅₀s of 42.19, 188.71 and 354.15 nM for CDK1, CDK2 and CDK5, respectively. CDK1-IN-5 inhibits growth of cancer cells by affecting cell cycle. CDK1-IN-5 can be used for the research of cancer .

HY-151407

CDK1-IN-3	CDK	Cancer
CDK1-IN-3 (8g) is a selective *CDK1* inhibitor with IC₅₀s of 36.8, 305.17 and 369.37 nM for CDK1, CDK2 and CDK5, respectively. CDK1-IN-3 inhibits the growth of cancer cells by affecting cell cycle. CDK1-IN-3 can be used for the research of cancer .

HY-151408

CDK1-IN-4	CDK	Cancer
CDK1-IN-4 (10d) is a selective *CDK1* inhibitor with IC₅₀s of 44.52, 624.93 and 135.22 nM for CDK1, CDK2 and CDK5, respectively. CDK1-IN4 inhibits the growth of cancer cells by affecting cell cycle. CDK1-IN-4 can be used for the research of cancer .

HY-145394

CDK7-IN-6	CDK	Cancer
CDK7-IN-6 is a potent and selective cyclin-dependent kinase (CDK7) inhibitor (IC₅₀≤100 nM), extracted from patent WO2019197549 A1, compound 210. CDK7-IN-6 is > 200-fold selective for CDK7 over CDK1, CDK2, and CDK5. CDK7-IN-6 can be used for the research of cancer .

HY-103712A

Samuraciclib hydrochloride 5+ Cited Publications CT7001 hydrochloride; ICEC0942 hydrochloride	CDK Apoptosis	Cancer
Samuraciclib hydrochloride (CT7001 hydrochloride) is a potent, selective, ATP-competitive and orally active CDK7 inhibitor, with an IC₅₀ of 41 nM. Samuraciclib hydrochloride displays 45-, 15-, 230- and 30-fold selectivity over CDK1, CDK2 (IC₅₀ of 578 nM), CDK5 and CDK9, respectively. Samuraciclib hydrochloride inhibits the growth of breast cancer cell lines with GI₅₀ values between 0.2-0.3 µM. Samuraciclib hydrochloride has anti-tumor effects .

HY-103712B

Samuraciclib hydrochloride hydrate 5+ Cited Publications CT7001 hydrochloride hydrate; ICEC0942 hydrochloride hydrate	CDK Apoptosis	Cancer
Samuraciclib (CT7001) hydrochloride hydrate is a potent, selective, ATP-competitive and orally active CDK7 inhibitor, with an IC₅₀ of 41 nM. Samuraciclib hydrochloride hydrate displays 45-, 15-, 230- and 30-fold selectivity over CDK1, CDK2 (IC₅₀ of 578 nM), CDK5 and CDK9, respectively. Samuraciclib hydrochloride hydrate inhibits the growth of breast cancer cell lines with GI₅₀ values between 0.2-0.3 µM. Samuraciclib hydrochloride hydrate has anti-tumor effects .

HY-103712

Samuraciclib CT7001; ICEC0942	CDK Apoptosis	Cancer
Samuraciclib (CT7001) is a potent, selective, ATP-competitive and orally active CDK7 inhibitor, with an IC₅₀ of 41 nM. Samuraciclib displays 45-, 15-, 230- and 30-fold selectivity over CDK1, CDK2 (IC₅₀ of 578 nM), CDK5 and CDK9, respectively. Samuraciclib inhibits the growth of breast cancer cell lines with GI₅₀ values between 0.2-0.3 µM. Samuraciclib has anti-tumor effects .

HY-103712C

Samuraciclib hydrochloride hydrate 5+ Cited Publications CT7001 hydrochloride hydrate; ICEC0942 hydrochloride hydrate	CDK Apoptosis	Cancer
Samuraciclib (CT7001) hydrochloride hydrate is a potent, selective, ATP-competitive and orally active CDK7 inhibitor, with an IC₅₀ of 41 nM. Samuraciclib hydrochloride hydrate displays 45-, 15-, 230- and 30-fold selectivity over CDK1, CDK2 (IC₅₀ of 578 nM), CDK5 and CDK9, respectively. Samuraciclib hydrochloride hydrate inhibits the growth of breast cancer cell lines with GI₅₀ values between 0.2-0.3 µM. Samuraciclib hydrochloride hydrate has anti-tumor effects .

HY-151878

CDK7-IN-20	CDK GSK-3	Metabolic Disease
CDK7-IN-20 is a potent, selective and irreversible CDK7 (CDK) inhibitor with an IC₅₀ value of 4 nM. CDK7-IN-20 displays >206-fold selectivity for CDK7 over CDK1, CDK2, CDK3, CDK5, CDK6, CDK9 and CDK12 . CDK7-IN-20 has the potential for autosomal dominant polycystic kidney disease (ADPKD) research .

HY-146276

CDK/HDAC-IN-2	HDAC CDK Apoptosis	Cancer
CDK/HDAC-IN-2 is a potent HDAC/CDK dual inhibitor with IC₅₀ of 6.4, 0.25, 45, >1000, 8.63, 0.30, >1000 nM for HDAC1, HDAC2, HDAC3, HDAC6,8, CDK1, CDK2, CDK4,6,7, respectively. CDK/HDAC-IN-2 shows excellent antiproliferative activities. CDK/HDAC-IN-2 induces apoptosis and cell cycle arrest at G2/M phase. CDK/HDAC-IN-2 shows potent antitumor efficacy .

HY-146253

CDK1/2/4-IN-1	CDK Apoptosis Bcl-2 Family Caspase	Cancer
CDK1/2/4-IN-1 (compound 3a) is a potent CDK inhibitor with IC₅₀ values of 1.47, 0.78 and 0.87 μM for CDK1, CDK2 and CDK4, respectively. CDK1/2/4-IN-1 arrests cell cycle at G2/M phase and induces apoptosis. CDK1/2/4-IN-1 elevates Bax, caspase-3, P53 levels and decreases Bcl-2 level. CDK1/2/4-IN-1 can be used for cancer research .

Ribociclib-d8
Ribociclib-d₈ is the deuterium labeled Ribociclib[1]. Ribociclib (LEE01) is a highly specific CDK4/6 inhibitor with IC50 values of 10 nM and 39 nM, respectively, and is over 1,000-fold less potent against the cyclin B/CDK1 complex[2].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.